Opiatergic modulation of preparatory and consummatory components of feeding and drinking.
We present data here indicating that stimulation of kappa but not mu opiate receptors influences motivational and consummatory aspects of feeding and drinking. To differentiate mu and kappa mechanisms controlling preparatory (appetitive) and consummatory components of ingestive behavior, the effects of morphine (MORPH), compound U50488H (U50) and naloxone (NAL) were studied in rats trained to negotiate a straight runway using food or water as a reinforcer. At doses that increase feeding and drinking in conditions of free access to food and water (i.e., 1-2 mg/kg IP), MORPH affected neither food- nor water-maintained runway performance. Since 1 mg/kg of NAL is also devoid of effects, mu-opiate mechanisms are probably not involved in food- or water-maintained behavior. Pharmacological manipulation of kappa-opiate mechanisms had complex effects. At 5 mg/kg, NAL accelerated satiation, depressing food intake, without affecting running. U50 did not increase food intake, but accelerated running for food, an effect that was antagonized by a high dose of NAL (5 mg/kg). These findings suggest that motivational and consummatory components of food-maintained runway performance are both activated by kappa-opiate mechanisms. NAL also reduced water intake but had minimal influences on running. In contrast, U50 depressed both water intake and runway performance; rather than being antagonized, these effects were slightly enhanced by NAL. The combined antidipsic and diuretic effects of U50 suggest that kappa-opiate mechanisms play a dissipatory role in water balance. However, the similar antidipsic effects of U50 and NAL, and the fact that NAL did not antagonize the antidipsic effects of U50, suggest that U50 may reduce drinking by mechanisms other than kappa-opiate agonism.
Nencini
P
P
Institute of Medical Pharmacology, University La Sapienza, Rome, Italy.
Graziani
M
M
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000818:Animals; D003216:Conditioning, Operant / Q000187:drug effects; D004327:Drinking Behavior / Q000187:drug effects*; D005247:Feeding Behavior / Q000187:drug effects*; D005502:Food; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000502:physiology; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D012054:Reinforcement, Psychology
D009294:Narcotics; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009270:Naloxone; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D009020:Morphine